Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Allogeneic Hematopoietic Stem Cell Transplantation in Juvenile Myelomonocytic Leukemia

연소형 골수단구성 백혈병에서의 동종 조혈 모세포 이식

  • Yoo, Keon Hee (Department of Pediatrics, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine) ;
  • You, Dong Kil (Department of Pediatrics, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, Soo Hyun (Department of Pediatrics, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine) ;
  • Sung, Ki Woong (Department of Pediatrics, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine) ;
  • Cho, Eun Joo (Cancer Center, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine) ;
  • Koo, Hong Hoe (Department of Pediatrics, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine)
  • 유건희 (성균관대학교 의과대학 삼성서울병원 소아과) ;
  • 유동길 (성균관대학교 의과대학 삼성서울병원 소아과) ;
  • 이수현 (성균관대학교 의과대학 삼성서울병원 소아과) ;
  • 성기웅 (성균관대학교 의과대학 삼성서울병원 소아과) ;
  • 조은주 (성균관대학교 의과대학 삼성서울병원 암센터) ;
  • 구홍회 (성균관대학교 의과대학 삼성서울병원 소아과)
  • Received : 2004.09.13
  • Accepted : 2004.10.09
  • Published : 2005.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : The purpose of this study was to evaluate the outcome of children with juvenile myelomonocytic leukemia(JMML) treated with allogeneic hematopoietic stem cell transplantation(allo-HSCT). Methods : Eleven JMML patients aged 8-39 months underwent allo-HSCT. The sources of grafts were unrelated donors(n=7), HLA-matched siblings(n=3) and an HLA 1-antigen mismatched familial donor. All patients had received chemotherapy ${\pm}13$-cis-retinoic acid(CRA) before transplant, and CRA was used, posttransplant, in six patients. Results : Only three patients were in complete remission(CR) at the time of transplantation. Initial chimeric status revealed complete donor chimerism(CC) in five patients, mixed chimerism(MC) in five and autologous recovery(AR) in one. One patient with MC having persistent splenomegaly eventually turned to CC and CR after rapid tapering of cyclosporine, combined with daily use of CRA. An AR case relapsed shortly after transplant but was rescued with second, unrelated cord blood transplantation. Ultimately, six patients are alive, event-free, with a median follow-up of 15.5 months posttransplant. All three deaths occurred in patients who failed to achieve CC, leading to disease progression. Conclusion : We suggest that graft-versus-leukemia effect play an important role and CRA a possible role in posttransplant leukemic involution in JMML. In patients whose leukemic burden is still high with MC after transplant, early tapering of immunosuppressants and introduction of CRA might provide a chance of a cure for some patients.

목 적 : JMML은 소아에서 발생하는 매우 드문 종류의 백혈병으로서 통상적인 항암화학요법만으로는 완치가 어려워 동종 조혈 모세포 이식을 시행하여야 한다. 아직 국내에서는 본 질환의 조혈 모세포 이식 성적에 대한 보고가 없어 저자들은 단일기관에서 경험한 JMML 환자의 동종 조혈 모세포 이식 성적을 보고하고자 하였다. 방 법 : 8개월에서 39개월 된 11명의 JMML 환자를 대상으로 동종 조혈 모세포 이식을 시행하였다. 조혈 모세포의 공급원으로 비혈연 골수 혹은 제대혈 7례, HLA 일치 형제 공여자 3례, HLA 1 항원 불일치 가족 공여자 1례 등을 이용하였다. 모든 환자들은 이식 전 항암화학요법을 시행 받았고 일부 환자에게는 13-cis-retinoic acid(CRA)를 사용하였다. 결 과 : 총 11례 중 3례만이 이식 전 치료로 혈액학적 및 임상적 완전관해에 도달하였다. 이식 후 1개월째 첫 키메리즘 평가 결과 완전 공여자 키메리즘 5례, 혼합 키메리즘 5례, 자가회복 1례였다. 혼합 키메리즘 상태에서 비장종대가 해소되지 않았던 1례에서 면역억제제의 급속 감량과 함께 CRA를 지속적으로 투여한 결과 완전 공여자 키메리즘으로의 전환과 함께 완전관해가 유도되었다. 자가회복 되었던 1례는 이식 후 조기 재발하였으나 복합 항암화학요법과 CRA의 투여로 이차 완전관해가 유도되었다. 결과적으로 11례 중 6례가 이식 후 정중 추적기간 15.5개월간 무사건 생존 중이다. 사망한 3례는 모두 완전 공여자 키메리즘에 실패하였던 경우들로서 질병의 재발 혹은 진행이 사망의 원인이었다. 결 론 : 본 연구 결과 JMML의 근치에는 동종 조혈 모세포 이식 후 이식편대 백혈병 효과가 중요한 역할을 담당하며 CRA도 긍정적 역할을 가지는 것으로 사료된다. 이식 후에도 완전관해에 도달하지 못하고 혼합 키메리즘 양상을 보이는 경우, 면역 억제제를 조기 감량하는 정책과 함께 CRA를 도입함으로써 완치의 가능성을 높일 수 있을 것으로 기대된다.

Keywords

References

  1. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 1997;90:479-88
  2. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003;17:277-82 https://doi.org/10.1038/sj.leu.2402765
  3. Festa RS, Shende A, Lanzkowsky P. Juvenile chronic myelocytic leukemia : experience with intensive combination chemotherapy. Med Pediatr Oncol 1990;18:311-16 https://doi.org/10.1002/mpo.2950180411
  4. Yusuf U, Frangoul HA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 2004;33:805-14 https://doi.org/10.1038/sj.bmt.1704438
  5. Manabe A, Okamura J, Yumura-Yagi K, Akiyama Y, Sako M, Uchiyama H, et al. MDS Committee of the Japanese Society of Pediatric Hematology : allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002;16:645-49 https://doi.org/10.1038/sj.leu.2402407
  6. Baker D, Cole C, Price J, Phillips M. Allogeneic bone marrow transplantation in juvenile myelomonocytic leukemia without total body irradiation. J Pediatr Hematol Oncol 2004;26:200-3 https://doi.org/10.1097/00043426-200403000-00012
  7. Bunin N, Saunders F, Leahey A, Doyle J, Calderwood S, Freedman MH. Alternative donor bone marrow transplantation for children with juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol 1999;21:479-485 https://doi.org/10.1097/00043426-199911000-00008
  8. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood : a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood( EWOG-MDS). Blood 1997;89:3534-43
  9. Emanuel PD. Myelodysplasia and myeloproliferative disorders in childhood : an update. Br J Haematol 1999;105:852-63 https://doi.org/10.1111/j.1365-2141.1999.01435.x
  10. Lilleyman JS, Harrison JF, Black JA. Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine. Blood 1977;49:559-62
  11. Laver J, Kushner BH, Steinherz PG. Juvenile chronic myeloid leukemia: therapeutic insights. Leukemia 1987;1:730-3
  12. Toren A, Mandel M, Amariglio N, Hakim Y, Brok-Simoni F, Rechavi G, et al. Lack of bcr rearrangement in juvenile chronic myeloid leukemia. Med Pediatr Oncol 1991;19:493-5 https://doi.org/10.1002/mpo.2950190608
  13. Nakamura H, Sadamori N, Ichimaru M, Shigeno K, Kinoshita K, Ohyashiki JH, et al. Juvenile chronic myeloid leukemia : no rearrangement of the breakpoint cluster region. Cancer Genet Cytogenet 1988;36:227-9 https://doi.org/10.1016/0165-4608(88)90152-5
  14. Lee EY, Kim JT, Hong YS, Kim SK, Lee HK. A case of juvenile chronic myelogenous leukemia associated with juvenile xanthogranuloma. J Korean Pediatr Soc 1987;30: 1299-304
  15. Kim SC, Kim MY, Song KE, Suh JS, Lee WK, Kim JS. Juvenile chronic myelogenous leukemia developed in infant. Korean Soc Hematol 1989;24:41-6
  16. Chang YH, Jou ST, Lin DT, Lu MY, Lin KH. Second allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia : case report and literature review. J Pediatr Hematol Oncol 2004;26:190-3 https://doi.org/10.1097/00043426-200403000-00009
  17. Baurmann H, Nagel S, Binder T, Neubauer A, Siegert W, Huhn D. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood 1998;92:3582-90
  18. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A, et al. Comparison of single-dose and escalatingdose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95:67-71
  19. Worth A, Rao K, Webb D, Chessells J, Passmore J, Veys P. Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusion. Blood 2003;101:1713-4 https://doi.org/10.1182/blood-2002-07-2011
  20. MacMillan ML, Davies SM, Orchard PJ, Ramsay NK, Wagner JE. Haemopoietic cell transplantation in children with juvenile myelomonocytic leukaemia. Br J Haematol 1998;103:552-8 https://doi.org/10.1046/j.1365-2141.1998.00995.x
  21. Castleberry RP, Emanuel PD, Zuckerman KS, Cohn S, Strauss L, Byrd RL, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 1994;331:1680-4 https://doi.org/10.1056/NEJM199412223312503
  22. Kang HJ, Shin HY, Choi HS, Ahn HS. Novel regimen for the treatment of juvenile myelomonocytic leukemia(JMML). Leuk Res 2004;28:167-70 https://doi.org/10.1016/S0145-2126(03)00217-0